|
|
Line 599: |
Line 599: |
|
| |
|
| ==Mesonephric adenocarcinoma== | | ==Mesonephric adenocarcinoma== |
| ===General===
| | {{Main|Mesonephric adenocarcinoma}} |
| *Arises from the [[mesonephric duct remnants]].
| |
| | |
| ===Microscopic===
| |
| Features:<ref name=Ref_WMSP442>{{Ref WMSP|442}}</ref>
| |
| *Nuclear atypia - '''key feature'''.
| |
| **Nuclear crowding.
| |
| *Variable architecture:
| |
| **Tubular, papillary, solid, retiform (net-like<ref>URL: [http://www.thefreedictionary.com/retiform http://www.thefreedictionary.com/retiform]. Accessed on: 25 August 2012.</ref>).
| |
| | |
| DDx:
| |
| *[[Mesonephric duct remnants]].
| |
| *[[Cervical adenocarcinoma]].
| |
| *[[Colorectal adenocarcinoma]].
| |
| *Endometrioid adenocarcinoma.
| |
| | |
| ===IHC===
| |
| Features:<ref name=Ref_WMSP442>{{Ref WMSP|442}}</ref>
| |
| *CK7 +ve.
| |
| *CD10 +ve.
| |
| *AMACR +ve.
| |
| *Napsin A +ve.<ref name=pmid31361605>{{cite journal |authors=Pors J, Segura S, Cheng A, Ji JX, Tessier-Cloutier B, Cochrane D, Fix DJ, Park K, Gilks B, Hoang L |title=Napsin-A and AMACR are Superior to HNF-1β in Distinguishing Between Mesonephric Carcinomas and Clear Cell Carcinomas of the Gynecologic Tract |journal=Appl Immunohistochem Mol Morphol |volume=28 |issue=8 |pages=593–601 |date=September 2020 |pmid=31361605 |pmc=6987010 |doi=10.1097/PAI.0000000000000801 |url=}}</ref>
| |
| *HNF-1beta +ve/-ve.
| |
| **Not useful for differentiation from clear cell carcinoma of the gynecologic tract.<ref name=pmid31361605/>
| |
| | |
| Others:<ref name=Ref_WMSP442>{{Ref WMSP|442}}</ref>
| |
| *[[CK20]] -ve.
| |
| *ER -ve.
| |
| *PR -ve.
| |
| *CEA -ve.
| |
|
| |
|
| ==Minimal deviation adenocarcinoma of the uterine cervix== | | ==Minimal deviation adenocarcinoma of the uterine cervix== |